Ampersand Biomedicines Secures $65 Million in Series B Funding and Advances Lead Programs

Ampersand Biomedicines secures $65 million in Series B funding for disease-targeting medicines and advances lead programs.

AI-assisted, human-published

Latest headlines

Join us for funding and investment opportunities.

Stay connected!

If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here